Lincoln Pharmaceuticals Limited (LINCOLN) Fair Value & Analysis
Healthcare · IN · Market cap ₹12.5B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price +5.2% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹447.10 – ₹763.10 · fair‑value band ₹538.11 – ₹999.34 · the ₹624.25 price screens below the ₹745.99 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Lincoln Pharmaceuticals Limited (LINCOLN) currently trades at ₹624.25, while our model-based Fair Value estimate is ₹745.99 — implying the stock looks roughly 19.5% undervalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Lincoln Pharmaceuticals Limited generated revenue of ₹6.7B at a net margin of 13.1%. Revenue grew 11.4% year over year. It earns a return on equity of 12.3%. The balance sheet holds a net cash position of ₹282M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia. Lincoln Pharmaceuticals Limited was incorporated in 1979 and is based in Ahmedabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Lincoln Pharmaceuticals Limited reported revenue of ₹6.7B in FY2026 versus ₹4.7B in FY2022, a compound +9.4%/yr. Reported net income was ₹879M in FY2026, compounding +6.1%/yr from FY2022.
Is LINCOLN fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Lincoln Pharmaceuticals Limited (LINCOLN) undervalued?
What is the fair value of LINCOLN?
What is the quality score of LINCOLN?
What is the revenue of Lincoln Pharmaceuticals Limited (LINCOLN)?
What is the net profit margin of LINCOLN?
Does Lincoln Pharmaceuticals Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.